One study linked CD19+CD11c+T-bet+ atypical B cells to the development of clinically isolated syndrome (CIS) in de novo Epstein-Barr virus–positive (EBV-positive) patients (64). This evidence concerns the gene ITGAX and in situ carcinoma.